Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: MDR certification

This article was originally published in The Gray Sheet

Executive Summary

MDR certification: FDA sets May 19 as the effective date for manufacturer and distributor annual certification requirements under the agency's medical device reporting regulation, according to a final rule published in the March 20 Federal Register. The rule codifies language offered by FDA in a July 1996 proposed rule that a firm's statement certifying the number of MDR reports submitted to the agency in a given year (or that no MDRs had been submitted) be signed by a company official "with oversight responsibilities for, and knowledge of, the firm's MDR reporting system," and the company "may designate more than one certifying official, each of whom will sign a certification statement pertaining to their respective identified component(s) or sites(s)" ("The Gray Sheet" July 22, 1996, I&W-1). The only modification to the language in the final rule is the addition of a statement that the certification is being made "to the best of [the designated official's] knowledge and belief." As outlined in the December 1995 final MDR rule, certification was to be made by the company president or CEO. FDA stayed the certification requirement, which was to have gone into effect with the entire MDR rule on July 31, 1996, due to industry concerns of potential liability for inadvertent reporting errors...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT007814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel